Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23570188 | 0.88 | — | — | |
| SCHEMBL24785434 | 0.83 | — | — | |
| SCHEMBL28393770 | 0.78 | — | — | |
| SCHEMBL11455287 | 0.78 | POLB (0.31) | — | |
| SCHEMBL19266236 | 0.78 | — | — | |
| SCHEMBL22215157 | 0.78 | — | — | |
| SCHEMBL33524192 | 0.76 | ALDH1A1 (0.31) | — | |
| SCHEMBL23334738 | 0.76 | — | — | |
| SCHEMBL13700099 | 0.76 | — | — | |
| SCHEMBL22508551 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092138-A1 | BLOCKED POLYISOCYANATE COMPOSITION, CURABLE RESIN COMPOSITION COMPRISING THE COMPOSITION, AND CURED PRODUCT | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2026-04-02 | — | — | US | disclosed |
| EP-3664793-B1 | MACROCYCLIC IMMUNOMODULATORS | CHEMOCENTRYX INC (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3658522-B1 | IMMUNOMODULATOR COMPOUNDS | CHEMOCENTRYX INC (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020047035-A1 | METHODS OF TREATING CANCER WITH SMALL MOLECULE PD-L1 INHIBITORS | CHEMOCENTRYX, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| WO-2019032547-A1 | MACROCYCLIC IMMUNOMODULATORS | CHEMOCENTRYX, INC. (US) | 2019-02-14 | — | — | WO | disclosed |
| WO-2019023575-A1 | IMMUNOMODULATOR COMPOUNDS | CHEMOCENTRYX, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| US-20130059816-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-7919623-B2 | Naphthyridine derivatives having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-20090227621-A1 | Naphthyridine derivatives having inhibitory activity against hiv integrase | SHIONOGI & CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-7329663-B2 | Substituted-triazolopyrimidines as anticancer agents | WYETH (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329663-B2 | Substituted-triazolopyrimidines as anticancer agents | WYETH (US) | 2008-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | EPHX1 4407/4885 |
| US-20260092138-A1 | BLOCKED POLYISOCYANATE COMPOSITION, CURABLE RESIN COMPOSITION COMPRISING THE COMPOSITION, AND CURED PRODUCT | RER1, RPP30, REV1 | EPHX1 1855/4885 |
| US-20130059816-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | EPHX1 880/4885 |
| US-20090227621-A1 | Naphthyridine derivatives having inhibitory activity against hiv integrase | PNP, CDKL1, ASNS | EPHX1 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.